What Recursion Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 5 | 35 |
| Total trades | 12 | 103 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 103 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hershberg Robert | Director | Oct 06 | Open-market sale · S | −25,000 | $5.00 | −$125K | 162,156 |
| Hershberg Robert | Director | Oct 06 | Exercise / conversion · M | +25,000 | $2.22 | +$55.5K | 187,156 |
| Borgeson Blake | Director | Oct 06 | Open-market sale · S | −50,000 | $4.84 | −$242K | 6,108,287 |
| Li Dean Y | Director | Oct 01 | Grant / award · A | +3,378 | — | — | 1,476,707 |
| Dar Zavain | Director | Oct 01 | Grant / award · A | +4,607 | — | — | 245,371 |
| Taylor Ben R | Chief Financial Officer | Sep 15 | Withheld — tax / exercise cost · F | −5,396 | $3.41 | −$18.4K | 1,071,462 |
| Khan Najat | CEO and President | Sep 08 | Open-market sale · S | −22,408 | $3.52 | −$78.8K | 2,072,890 |
| Borgeson Blake | Director | Sep 01 | Open-market sale · S | −30,000 | $3.34 | −$100K | 6,158,287 |
| Khan Najat | CEO and President | Aug 17 | Withheld — tax / exercise cost · F | −80,498 | $3.16 | −$254K | 2,095,298 |
| Taylor Ben R | Chief Financial Officer | Aug 17 | Withheld — tax / exercise cost · F | −25,018 | $3.16 | −$79.1K | 1,076,858 |
| Hallett David | Chief Scientific Officer | Aug 17 | Withheld — tax / exercise cost · F | −26,657 | $3.16 | −$84.2K | 1,043,837 |
| Borgeson Blake | Director | Aug 04 | Open-market sale · S | −30,000 | $3.25 | −$97.5K | 6,188,287 |
| Borgeson Blake | Director | Jul 07 | Open-market sale · S | −40,000 | $3.96 | −$159K | 6,218,287 |
| Li Dean Y | Director | Jul 01 | Grant / award · A | +3,747 | — | — | 1,473,329 |
| Dar Zavain | Director | Jul 01 | Grant / award · A | +5,109 | — | — | 240,764 |
| Bumpus Namandje | Director | Jun 18 | Open-market sale · S | −3,963 | $3.18 | −$12.6K | 127,632 |
| Bumpus Namandje | Director | Jun 17 | Grant / award · A | +88,424 | — | — | 131,595 |
| Li Dean Y | Director | Jun 17 | Grant / award · A | +88,424 | — | — | 1,469,582 |
| Sun Elaine D | Director | Jun 17 | Grant / award · A | +88,424 | — | — | 135,981 |
| Michor Franziska | Director | Jun 17 | Grant / award · A | +88,424 | — | — | 215,477 |
Loading...
